S&P 500   4,387.45 (-0.51%)
DOW   34,427.60 (+0.18%)
QQQ   350.67 (-0.74%)
AAPL   161.25 (-0.23%)
MSFT   292.40 (-1.34%)
FB   303.84 (-1.58%)
GOOGL   2,566.76 (-1.89%)
AMZN   2,814.11 (-2.66%)
TSLA   940.26 (+1.10%)
NVDA   226.23 (-3.20%)
BABA   120.49 (+0.10%)
NIO   24.31 (-2.25%)
AMD   112.81 (-3.19%)
CGC   7.47 (+0.95%)
MU   81.69 (-1.52%)
GE   92.19 (-4.87%)
T   26.56 (+0.84%)
F   20.25 (-0.69%)
DIS   137.20 (-0.19%)
AMC   16.25 (-2.34%)
PFE   52.63 (+2.11%)
ACB   4.27 (-1.16%)
BA   204.94 (+0.36%)
S&P 500   4,387.45 (-0.51%)
DOW   34,427.60 (+0.18%)
QQQ   350.67 (-0.74%)
AAPL   161.25 (-0.23%)
MSFT   292.40 (-1.34%)
FB   303.84 (-1.58%)
GOOGL   2,566.76 (-1.89%)
AMZN   2,814.11 (-2.66%)
TSLA   940.26 (+1.10%)
NVDA   226.23 (-3.20%)
BABA   120.49 (+0.10%)
NIO   24.31 (-2.25%)
AMD   112.81 (-3.19%)
CGC   7.47 (+0.95%)
MU   81.69 (-1.52%)
GE   92.19 (-4.87%)
T   26.56 (+0.84%)
F   20.25 (-0.69%)
DIS   137.20 (-0.19%)
AMC   16.25 (-2.34%)
PFE   52.63 (+2.11%)
ACB   4.27 (-1.16%)
BA   204.94 (+0.36%)
S&P 500   4,387.45 (-0.51%)
DOW   34,427.60 (+0.18%)
QQQ   350.67 (-0.74%)
AAPL   161.25 (-0.23%)
MSFT   292.40 (-1.34%)
FB   303.84 (-1.58%)
GOOGL   2,566.76 (-1.89%)
AMZN   2,814.11 (-2.66%)
TSLA   940.26 (+1.10%)
NVDA   226.23 (-3.20%)
BABA   120.49 (+0.10%)
NIO   24.31 (-2.25%)
AMD   112.81 (-3.19%)
CGC   7.47 (+0.95%)
MU   81.69 (-1.52%)
GE   92.19 (-4.87%)
T   26.56 (+0.84%)
F   20.25 (-0.69%)
DIS   137.20 (-0.19%)
AMC   16.25 (-2.34%)
PFE   52.63 (+2.11%)
ACB   4.27 (-1.16%)
BA   204.94 (+0.36%)
S&P 500   4,387.45 (-0.51%)
DOW   34,427.60 (+0.18%)
QQQ   350.67 (-0.74%)
AAPL   161.25 (-0.23%)
MSFT   292.40 (-1.34%)
FB   303.84 (-1.58%)
GOOGL   2,566.76 (-1.89%)
AMZN   2,814.11 (-2.66%)
TSLA   940.26 (+1.10%)
NVDA   226.23 (-3.20%)
BABA   120.49 (+0.10%)
NIO   24.31 (-2.25%)
AMD   112.81 (-3.19%)
CGC   7.47 (+0.95%)
MU   81.69 (-1.52%)
GE   92.19 (-4.87%)
T   26.56 (+0.84%)
F   20.25 (-0.69%)
DIS   137.20 (-0.19%)
AMC   16.25 (-2.34%)
PFE   52.63 (+2.11%)
ACB   4.27 (-1.16%)
BA   204.94 (+0.36%)
NASDAQ:IMVT

Immunovant Stock Forecast, Price & News

$7.13
+0.19 (+2.74%)
(As of 01/25/2022 02:56 PM ET)
Add
Compare
Today's Range
$6.63
$7.15
50-Day Range
$6.57
$8.77
52-Week Range
$6.28
$43.49
Volume
17,646 shs
Average Volume
767,896 shs
Market Capitalization
$819.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.7
30 days | 90 days | 365 days | Advanced Chart
Receive IMVT News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.


Immunovant logo

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMVT
Fax
N/A
Employees
68
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$4.00 per share

Profitability

Net Income
$-107.43 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
112,815,000
Market Cap
$819.95 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/05/2021
Today
1/25/2022
Next Earnings (Estimated)
2/15/2022
Fiscal Year End
3/31/2022

MarketRank

Overall MarketRank

2.13 out of 5 stars

Medical Sector

492nd out of 1,416 stocks

Biological Products, Except Diagnostic Industry

73rd out of 206 stocks

Analyst Opinion: 3.2Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












Immunovant (NASDAQ:IMVT) Frequently Asked Questions

Is Immunovant a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Immunovant stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMVT, but not buy additional shares or sell existing shares.
View analyst ratings for Immunovant
or view top-rated stocks.

How has Immunovant's stock price been impacted by Coronavirus?

Immunovant's stock was trading at $14.14 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IMVT shares have decreased by 50.2% and is now trading at $7.04.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Immunovant?

Immunovant saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 2,310,000 shares, a decrease of 28.3% from the December 15th total of 3,220,000 shares. Based on an average daily volume of 635,700 shares, the short-interest ratio is currently 3.6 days. Approximately 5.7% of the shares of the stock are sold short.
View Immunovant's Short Interest
.

When is Immunovant's next earnings date?

Immunovant is scheduled to release its next quarterly earnings announcement on Tuesday, February 15th 2022.
View our earnings forecast for Immunovant
.

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) announced its quarterly earnings results on Friday, November, 5th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.09.
View Immunovant's earnings history
.

What price target have analysts set for IMVT?

10 brokerages have issued 1-year price targets for Immunovant's shares. Their forecasts range from $7.00 to $35.00. On average, they expect Immunovant's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 113.1% from the stock's current price.
View analysts' price targets for Immunovant
or view top-rated stocks among Wall Street analysts.

Who are Immunovant's key executives?

Immunovant's management team includes the following people:
  • Dr. Peter Salzmann M.B.A., M.D., CEO & Director (Age 53, Pay $1.02M)
  • Ms. Pamela Yanchik Connealy M.B.A., Chief Financial Officer (Age 59, Pay $558.94k)
  • Dr. Julia G. Butchko Ph.D., Chief Devel. & Technology Officer (Age 50, Pay $531k)
  • Ms. Lauren Schrier M.B.A., VP of Marketing
  • Ms. Beverly Paperiello, Sr. VP of Program Strategy, Chief Medical Officer & Chief of Staff
  • Dr. Alan Jacobs M.D., VP & Head of Neurology Devel.
  • Dr. William L. Macias M.D., Ph.D., Chief Medical Officer (Age 63)

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include salesforce.com (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).

What is Immunovant's stock symbol?

Immunovant trades on the NASDAQ under the ticker symbol "IMVT."

Who are Immunovant's major shareholders?

Immunovant's stock is owned by many different retail and institutional investors. Top institutional shareholders include Strs Ohio (0.02%). Company insiders that own Immunovant stock include Atul Pande, Douglas J Hughes, George V Migausky, Julia G Butchko, Sciences Ltd Roivant and William L Macias.
View institutional ownership trends for Immunovant
.

Which institutional investors are buying Immunovant stock?

IMVT stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought Immunovant stock in the last two years include Atul Pande, Douglas J Hughes, George V Migausky, Julia G Butchko, and Sciences Ltd Roivant.
View insider buying and selling activity for Immunovant
or or view top insider-buying stocks.

How do I buy shares of Immunovant?

Shares of IMVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunovant's stock price today?

One share of IMVT stock can currently be purchased for approximately $7.04.

How much money does Immunovant make?

Immunovant has a market capitalization of $809.60 million. The company earns $-107.43 million in net income (profit) each year or ($1.27) on an earnings per share basis.

How many employees does Immunovant have?

Immunovant employs 68 workers across the globe.

What is Immunovant's official website?

The official website for Immunovant is www.immunovant.com.

Where are Immunovant's headquarters?

Immunovant is headquartered at 320 WEST 37TH STREET, NEW YORK NY, 10018.

How can I contact Immunovant?

Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The company can be reached via phone at 917-580-3099 or via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.